slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,557
Current window 41,551-41,580
Pages 2,019
Rows per page 30
Component
41,551-41,580 of 60,557
11
The slide combines a biological pathway diagram (left) with a quantitative market sizing table (right).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
12
The kinome tree visualization (KINOMEscan) is a standard industry tool for demonstrating kinase selectivity.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
13
The slide combines a biological pathway diagram (mechanism of action) with a clinical trial summary table.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
15
The slide highlights the poor efficacy of current SOC and suggests binimetinib as a superior alternative.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
16
Waterfall plot uses standard clinical trial terminology (PD, SD, PR). Comparison table highlights the study drug's performance against Dacarbazine and Binimetinib.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
19
The slide highlights consistent clinical activity across two study phases, culminating in a combined ORR of 33.3%.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
24
The slide uses a biological signaling pathway map to justify combination therapy strategy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
25
The diagram shows the RAS/MAPK signaling pathway. The table provides a breakdown of patient populations for specific indications.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
30
Data cut 23MAR2023. Table shows frequency of specific adverse events by severity grade and dosage cohort.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
34
Includes RECIST 1.1 criteria reference and specific tumor measurements over time.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
35
The table displays counts and percentages of patients experiencing specific adverse events, categorized by severity (All vs Grade >= 3).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
36
The diagram shows the EGFR signaling pathway leading to MAPK and PI3K pathways.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
37
The slide uses a stacked bar chart to show mutation incidence and a comparison table to highlight clinical trial failures in GBM despite success in other indications.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
38
The slide uses Western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
42
The slide uses a table format to communicate a product development roadmap.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Quick Win Big Bet1 hit
48
The slide uses western blot data to demonstrate the efficacy of ERAS-007 in a specific biological pathway context.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
49
The slide uses a before-and-after imaging comparison to show clinical efficacy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
52
Data from HERKULES-1 study, cutoff 23 May 2022.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
53
The slide compares various dosing schedules (QW, BID-QW, BIW) against IC90 and IC50 thresholds.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
30
Page 30 of the deck.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations 1 hit
31
Q2 2023 Financial ResultsEtsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations 1 hit
32
Page 32 of a financial results deck.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations 1 hit
33
Page number 33, Q2 2023 Financial Results.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations 1 hit
34
Standard financial reconciliation table found in investor relations decks.Etsy | Investor Presentation Deck | 34 slides · Etsy
Pitch deck Investor relations 1 hit
18
The slide uses a 'gifting accomplice' framing to position the brand.Etsy | Results Presentation Deck | 42 slides · Etsy
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
33
Includes disclaimer regarding non-GAAP reconciliation and assumptions about currency and divestiture.Etsy | Results Presentation Deck | 42 slides · Etsy
Conference presentation Investor relations 1 hit
36
The slide presents financial data in thousands of dollars.Etsy | Results Presentation Deck | 42 slides · Etsy
Conference presentation Investor relations 1 hit
37
Page 37 of the presentation deck.Etsy | Results Presentation Deck | 42 slides · Etsy
Conference presentation Investor relations 1 hit
38
Page 38 of a financial presentation.Etsy | Results Presentation Deck | 42 slides · Etsy
Conference presentation Investor relations 1 hit
39
Standard financial reporting slide.Etsy | Results Presentation Deck | 42 slides · Etsy
Conference presentation Investor relations 1 hit